Correlation Between Nautilus Biotechnology and Candel Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Nautilus Biotechnology and Candel Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Nautilus Biotechnology and Candel Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Nautilus Biotechnology and Candel Therapeutics, you can compare the effects of market volatilities on Nautilus Biotechnology and Candel Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Nautilus Biotechnology with a short position of Candel Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Nautilus Biotechnology and Candel Therapeutics.

Diversification Opportunities for Nautilus Biotechnology and Candel Therapeutics

0.8
  Correlation Coefficient

Very poor diversification

The 3 months correlation between Nautilus and Candel is 0.8. Overlapping area represents the amount of risk that can be diversified away by holding Nautilus Biotechnology and Candel Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Candel Therapeutics and Nautilus Biotechnology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Nautilus Biotechnology are associated (or correlated) with Candel Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Candel Therapeutics has no effect on the direction of Nautilus Biotechnology i.e., Nautilus Biotechnology and Candel Therapeutics go up and down completely randomly.

Pair Corralation between Nautilus Biotechnology and Candel Therapeutics

Given the investment horizon of 90 days Nautilus Biotechnology is expected to generate 8.22 times less return on investment than Candel Therapeutics. But when comparing it to its historical volatility, Nautilus Biotechnology is 3.72 times less risky than Candel Therapeutics. It trades about 0.03 of its potential returns per unit of risk. Candel Therapeutics is currently generating about 0.07 of returns per unit of risk over similar time horizon. If you would invest  173.00  in Candel Therapeutics on September 12, 2024 and sell it today you would earn a total of  1,178  from holding Candel Therapeutics or generate 680.92% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthStrong
Accuracy100.0%
ValuesDaily Returns

Nautilus Biotechnology  vs.  Candel Therapeutics

 Performance 
       Timeline  
Nautilus Biotechnology 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Nautilus Biotechnology has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.
Candel Therapeutics 

Risk-Adjusted Performance

8 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Candel Therapeutics are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. Despite quite unsteady fundamental indicators, Candel Therapeutics disclosed solid returns over the last few months and may actually be approaching a breakup point.

Nautilus Biotechnology and Candel Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Nautilus Biotechnology and Candel Therapeutics

The main advantage of trading using opposite Nautilus Biotechnology and Candel Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Nautilus Biotechnology position performs unexpectedly, Candel Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Candel Therapeutics will offset losses from the drop in Candel Therapeutics' long position.
The idea behind Nautilus Biotechnology and Candel Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.

Other Complementary Tools

AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital